NVO
Novo Nordisk A/S
Stock
$37.32−0.08 (−0.21%)Close Oct 2, 2026
Income statement
| Line | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | DKK 309.1B | DKK 290.4B | DKK 232.3B | DKK 177.0B | DKK 140.8B | DKK 126.9B | DKK 122.0B |
| Cost of revenue | DKK 58.8B | DKK 44.5B | DKK 35.8B | DKK 28.4B | DKK 23.7B | DKK 20.9B | DKK 20.1B |
| Gross profit | DKK 250.3B | DKK 245.9B | DKK 196.5B | DKK 148.5B | DKK 117.1B | DKK 106.0B | DKK 101.9B |
| R&D | DKK 52.0B | DKK 48.1B | DKK 32.4B | DKK 24.0B | DKK 17.8B | DKK 15.5B | DKK 14.2B |
| Other operating expenses | DKK 70.6B | DKK 69.5B | DKK 61.5B | DKK 49.7B | DKK 40.7B | DKK 36.4B | DKK 35.2B |
| Operating income | DKK 127.7B | DKK 128.3B | DKK 102.6B | DKK 74.8B | DKK 58.6B | DKK 54.1B | DKK 52.5B |
| Non-operating income | DKK 2.9B | −DKK 1.1B | DKK 2.1B | −DKK 5.7B | DKK 436M | −DKK 996M | −DKK 3.9B |
| Pretax income | DKK 130.5B | DKK 127.2B | DKK 104.7B | DKK 69.1B | DKK 59.1B | DKK 53.1B | DKK 48.6B |
| Taxes | DKK 28.1B | DKK 26.2B | DKK 21.0B | DKK 13.5B | DKK 11.3B | DKK 11.0B | DKK 9.6B |
| Net income | DKK 102.4B | DKK 101.0B | DKK 83.7B | DKK 55.5B | DKK 47.8B | DKK 42.1B | DKK 39.0B |
| Diluted EPS | DKK 23.03 | DKK 22.63 | DKK 18.62 | DKK 12.22 | DKK 10.37 | DKK 18.01 | DKK 16.38 |
| Diluted shares | 4.45B | 4.46B | 4.49B | 4.54B | 4.61B | 2.34B | 2.38B |
| Revenue growth | +6.4% | +25.0% | +31.3% | +25.7% | +10.9% | +4.0% | — |
| Gross margin | 81.0% | 84.7% | 84.6% | 83.9% | 83.2% | 83.5% | 83.5% |
| Operating margin | 41.3% | 44.2% | 44.2% | 42.3% | 41.7% | 42.6% | 43.0% |
| Net margin | 33.1% | 34.8% | 36.0% | 31.4% | 33.9% | 33.2% | 31.9% |